Skip to main content

MDT

Stock
Health Care
Medical Devices

Performance overview

MDT Price
Price Chart

Forward-looking statistics

Beta
0.36
Risk
21.68%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Medtronic plc is an American medical device company. The companys operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien in 2015.

Company info

SectorHealth Care
IndustryMedical Devices
Employees95K
Market cap$110.2B

Fundamentals

Enterprise value$132.6B
Revenue$33.5B
Revenue per employee
Profit margin13.90%
Debt to equity61.39

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$3.61
Dividend per share$2.80
Revenue per share$26.09
Avg trading volume (30 day)$793M
Avg trading volume (10 day)$809M
Put-call ratio

Macro factor sensitivity

Growth-0.2
Credit+3.0
Liquidity+0.3
Inflation-1.9
Commodities-0.4
Interest Rates-1.5

Valuation

Dividend yield3.17%
PEG Ratio15.11
Price to sales3.38
P/E Ratio15.11
Enterprise Value to Revenue3.95
Price to book2.36

Upcoming events

Next earnings dayAugust 19, 2025
Next dividend day
Ex. dividend dayJune 27, 2025

News

Medtronic (MDT) Beats Stock Market Upswing: What Investors Need to Know

Medtronic (MDT) closed the most recent trading day at $87.17, moving +1.34% from the previous trading session.

Zacks Investment Research (June 30, 2025)
Medtronic Is Separating Its Diabetes Business - Good News For Investors

Medtronic plc MDT announced on May 21 its plans to separate its Diabetes business into a separate, publicly traded company. The separation will occur via a two step transaction – an initial minority IPO carve-out followed by a split-off of the remaining stake.

Benzinga (June 13, 2025)
Medtronic Announces Intent To Spin Diabetes Business

Deal OverviewOn May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business into a standalone entity (New Diabetes Company). This strategic move is designed to streamline Medtronic's portfolio, sharpen its focus on high-margin growth areas, and unlock shareholder value.

Forbes (June 9, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free